Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Eleventh Edition of the Report on Carcinogens

The Department of Health and Human Services released its Eleventh Edition of the Report on Carcinogens today, adding seventeen substances to the growing list of cancer-causing agents, bringing the total to 246.

31 Jan 2005

Why some men develop aggressive prostate cancer that becomes resistant to hormone-withdrawal therapy

Researchers found that certain mutations in a protein called the androgen receptor cause advanced and invasive prostate cancer when put into otherwise healthy mice. The androgen receptor's normal function is to control growth of the prostate gland in response to cues from male hormones called androgens, which have long been thought to stimulate prostate tumors.

26 Jan 2005

Research may provide the basis for development of a new, extensive immunotherapy for human tumors

Scientists have made significant progress towards understanding how the immune system can be more specifically and efficiently targeted against cancer cells. The research, published in the January issue of Immunity, may provide the basis for development of a new, extensive immunotherapy for human tumors.

26 Jan 2005

New highly active agents against leishmaniasis

Parasitic diseases, especially leishmaniases and trypanosomiases, kill hundreds of thousands of people every year in the world, mainly in the countries of the South. The most severe form of leishmaniosis (kala-azar, the visceral form), induced by Leishmania donovani and L. infantum, affects about 500 000 people per year and proves fatal if no treatment is given.

25 Jan 2005

New blood tests to soon replace painful bone marrow biopsies for leukemia and lymphoma patients

Quest Diagnostics Incorporated announced today that The University of Texas M. D. Anderson Cancer Center in Houston has granted the company exclusive use of five proprietary blood testing methods, which, once available in the form of laboratory diagnostic tests, may eliminate the need for painful and expensive bone marrow and other tissue extractions.

24 Jan 2005

Cord blood transplantation now a viable option for adult leukemia patients

Stem cell transplantation using umbilical cord blood is a standard treatment option for blood disorders in children, but not for adults, due to the difficulty of obtaining a sufficiently large dose of cells.

20 Jan 2005

FDA knocks back anticancer drug Marqibo

Inex Pharmaceuticals announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqibo (vincristine sulfate liposomes injection) is "not approvable" under the FDA's accelerated approval regulations based on the phase 2 clinical trial data submitted.

19 Jan 2005

Prenatal exposure to industrial and environmental pollutants probably causes most childhood cancers

Most childhood cancers are "probably" down to prenatal exposure to industrial and environmental pollutants, most likely to have been inhaled by the mother during pregnancy, suggests research in the Journal of Epidemiology and Community Health.

16 Jan 2005

Researchers to test new leukemia drug

Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.

12 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Glia cells may be essential for the normal development of nerve cells responsible for hearing and balance

Traditionally viewed as supporting actors, cells known as glia may be essential for the normal development of nerve cells responsible for hearing and balance, according to new University of Utah research. The study is reported in the January 6, 2005 issue of Neuron and is co-authored by scientists at the University of Washington.

6 Jan 2005

First new leukemia treatment approved specifically for children in more than a decade

Ash Stevens was approved to manufacture the bulk drug substance Clofarabine, the active ingredient in Genzyme Corp.'s Clolar (clofarabine) for the treatment of children with refractory or relapsed Acute Lymphoblastic Leukemia (ALL). This is the first new leukemia treatment approved specifically for children in more than a decade.

4 Jan 2005

Chemotherapy lowers levels of antioxidants and micronutrients

Children undergoing chemotherapy for acute lymphoblastic leukemia (ALL) have significant changes in their antioxidant and micronutrient status which are related to their treatment outcomes, according to the results of a novel prospective study.

28 Dec 2004

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Researchers have discovered that specific cancer-causing genes associated with leukemias can transform mature white blood cells into leukemic cells that have all the properties of stem cells.

21 Dec 2004

Essential oils have been found to kill the deadly MRSA bacteria

Essential oils usually used in aromatherapy have been found to kill the deadly MRSA bacteria according to research carried out at The University of Manchester.

From The University of Manchester 21 Dec 2004

Gene therapy effective in helping children with severe combined immunodeficiency (SCID)

A UK study in this week’s issue of THE LANCET provides further evidence that gene therapy can be effective in creating a functional immune system for infants with severe combined immunodeficiency (SCID).

20 Dec 2004

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Zarnestra, a farnesyl transferase inhibitor, can help treat high-risk myelodysplastic syndrome patients

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

7 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.